Miles Shen

Miles Shen

Auto-generated profile, based on publicly available information

Miles Shen

Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
MSMiles Shen
Miles Shen
AMAidan Milner
Aidan Milner
CPCarlo Foppiano Palacios
Carlo Foppiano Palacios
TATariq Ahmad
Tariq Ahmad
Background: During the Coronavirus disease 2019 (COVID-19) pandemic, reports have emerged of a multisystem inflammatory syndrome in adults (MIS-A). Multisystem inflammatory syndrome in adults can affect various organ systems, including cardiovascular, gastrointestinal, and neurologic systems without significant respiratory involvement. Case summary: A previously healthy 43-year-old man presented with fevers and abdominal pain then rapidly deteriorated into cardiogenic shock. His constellation of symptoms along with elevated inflammatory markers in the setting of a recent SARS-CoV-2 infection was consistent with the diagnosis of MIS-A. He also had a comprehensive infectious workup that was unremarkable, ruling out other potential infectious aetiologies for his presentation. He subsequently improved through supportive measures and after administration of intravenous immunoglobulin (IVIG). He later demonstrated recovery of cardiac function and cardiac magnetic resonance imaging (MRI) showed signs consistent with myocarditis. Discussion: As the COVID-19 pandemic continues to be an ongoing issue, it is important to recognize MIS-A, a rare and potentially deadly clinical syndrome that can lead to profound cardiovascular complications. Non-invasive imaging modalities such as cardiac MRI can play a role in the identification of myocarditis. In addition to supportive management, adjunctive therapies such as IVIG may be efficacious in MIS-A and should be further investigated.

2 December 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JKJennifer M Kwan
Jennifer M Kwan
MSMiles Shen
Miles Shen
NANarjes Akhlaghi
Narjes Akhlaghi
JHJiun-Ruey Hu
Jiun-Ruey Hu
RMRuben Mora
Ruben Mora
LBLauren A Baldassarre
Lauren A Baldassarre
Background: There is an urgent need to better understand the diverse presentations, risk factors, and outcomes of immune checkpoint inhibitor (ICI)-associated cardiovascular toxicity. There remains a lack of consensus surrounding cardiovascular screening, risk stratification, and clinical decision-making in patients receiving ICIs. Methods: We conducted a single center retrospective cohort study including 2165 cancer patients treated with ICIs between 2013 and 2020. The primary outcome was adverse cardiovascular events (ACE): a composite of myocardial infarction, coronary artery disease, stroke, peripheral vascular disease, arrhythmias, heart failure, valvular disease, pericardial disease, and myocarditis. Secondary outcomes included all-cause mortality and the individual components of ACE. We additionally conducted an imaging substudy examining imaging characteristics from echocardiography (echo) and cardiac magnetic resonance (CMR) imaging. Results: In our cohort, 44% (n = 962/2165) of patients experienced ACE. In a multivariable analysis, dual ICI therapy (hazard ratio [HR] 1.23, confidence interval [CI] 1.04–1.45), age (HR 1.01, CI 1.00–1.01), male sex (HR 1.18, CI 1.02–1.36), prior arrhythmia (HR 1.22, CI 1.03–1.43), lung cancer (HR 1.17, CI 1.01–1.37), and central nervous system (CNS) malignancy (HR 1.23, CI 1.02–1.47), were independently associated with increased ACE. ACE was independently associated with a 2.7-fold increased risk of mortality (P<0.001). Dual ICI therapy was also associated with a 2.0-fold increased risk of myo/pericarditis (P = 0.045), with myo/pericarditis being associated with a 2.9-fold increased risk of mortality (P<0.001). However, the cardiovascular risks of dual ICI therapy were offset by its mortality benefit, with dual ICI therapy being associated with a ~25% or 1.3-fold decrease in mortality. Of those with echo prior to ICI initiation, 26% (n = 115/442) had abnormal left ventricular ejection fraction or global longitudinal strain, and of those with echo after ICI initiation, 28% (n = 207/740) had abnormalities. Of those who had CMR imaging prior to ICI initiation, 43% (n = 9/21) already had left ventricular dysfunction, 50% (n = 10/20) had right ventricular dysfunction, 32% (n = 6/19) had left ventricular late gadolinium enhancement, and 9% (n = 1/11) had abnormal T2 imaging. Conclusion: Dual ICI therapy, prior arrhythmia, older age, lung and CNS malignancies were independently associated with an increased risk of ACE, and dual ICI therapy was also independently associated with an increased risk of myo/pericarditis, highlighting the utmost importance of cardiovascular risk factor optimization in this particularly high-risk population. Fortunately, the occurrence of myo/pericarditis was relatively uncommon, and the overall cardiovascular risks of dual ICI therapy appeared to be offset by a significant mortality benefit. The use of multimodal cardiac imaging can be helpful in stratifying risk and guiding preventative cardiovascular management in patients receiving ICIs.

14 September 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MSMiles Shen
Miles Shen
ANArash Aghajani Nargesi
Arash Aghajani Nargesi
KNKhurram Nasir
Khurram Nasir
DBDeepak L Bhatt
Deepak L Bhatt
RKRohan Khera
Rohan Khera
Background: The emergence of PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitor) and icosapent ethyl (IPE) has expanded the role of lipid‐lowering therapies beyond statins. Despite recommendations by clinical practice guidelines, their national eligibility and use rates remain unclear. Methods and Results: In the National Health and Nutrition Examination Survey data from 2017 to 2020, we assessed eligibility and the use of statins, PCSK9i, and IPE among US adults according to American College of Cardiology/American Heart Association guideline recommendations. Eligibility for PCSK9i and IPE were determined in the following 2 scenarios: (1) assuming existing lipid‐lowering therapy as the maximum tolerated before assessing eligibility for novel therapies and (2) assessing eligibility after assuming initiation and maximal escalation of preexisting lipid‐lowering therapies and accounting for expected lipid improvements. Of 2729 sampled individuals, representing 149.3 million adults, 1376 had indications for statins, representing 65.8 million or 44.0% (95% CI, 40.9%–47.2%) of adults. Current statin use was 45% of those eligible and was low across demographic groups. A total of 9.7 and 11.6 million adults would benefit from PCSK9i and IPE, respectively, based on lipid profiles and existing therapies. Assuming maximal escalation of statins and addition of ezetimibe, 4.1% (95% CI, 2.8%–5.4%) of adults or 6.1 million would benefit from PCSK9i and 6.8% (95% CI, 5.4%–8.3%) or 10.2 million from IPE. Conclusions: Six and 10 million individuals have clinical profiles whereby PCSK9i and IPE, respectively, would be expected to improve cardiovascular outcomes even after maximum escalation of statins and ezetimibe use, but remain undertreated with lipid‐lowering therapies. Optimal use of lipid‐targeted agents that include these novel agents is needed to improve population health outcomes.

18 November 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
TZTalal El Zarif
Talal El Zarif
AAAlexander P. Ambrosini
Alexander P. Ambrosini
ASAndi Shahu
Andi Shahu
MSMiles Shen
Miles Shen
MGMaria G. Gastanadui
Maria G. Gastanadui
EMElliott Miller
Elliott Miller
Background: There are limited data on the management of myocarditis‐associated cardiogenic shock. The aim of this study was to assess the clinical outcomes of patients with myocarditis‐associated cardiogenic shock. Methods: In this retrospective study using the Vizient Clinical Data Base, patients aged ≥18 years admitted with cardiogenic shock during 2015 through 2023 across the United States were stratified by myocarditis status. We assessed in‐hospital death by augmented inverse probability weighting, accounting for demographics, comorbidities, critical care therapies, and hospital characteristics. Results: A total of 621 695 patients with cardiogenic shock were included. Patients with myocarditis (n=2925; 0.5%) were younger (49.9 versus 65.2 years), more likely to be women (45.9% versus 36.7%), and had a lower Charlson comorbidity index (3.6 versus 4.4) but higher rates of cancer (13.5% versus 7.5%) and rheumatic disease (8.3% versus 3.4%) (all P <0.001). They required more inotropic medications (56.9% versus 41.3%) and mechanical circulatory support (35.2% versus 19.3%) and more invasive procedures such as left ventricular assist device implantation (4.5% versus 2.3%) and heart transplantation (5.0% versus 1.8%), left heart catheterization (33.1% versus 26.0%), and pulmonary artery catheterization (49.5% versus 26.3%), but fewer percutaneous coronary interventions (2.0% versus 12.1%) or coronary artery bypass grafting (0.8% versus 7.5%) (all P <0.001). Following augmented inverse probability weighting, myocarditis was associated with a higher adjusted mortality rate (+9.8% [95% CI, 4.0–15.5]; P =0.001). Conclusions: Myocarditis‐associated cardiogenic shock is uncommon yet represents a critically ill population with a higher adjusted in‐hospital mortality rate. Future work investigating therapies for this unique patient population is warranted.

29 December 2025 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SKSohum Kapadia
Sohum Kapadia
MSMiles Shen
Miles Shen
JHJonathan Hanna
Jonathan Hanna
KWKevin Wheelock
Kevin Wheelock
APAline F. Pedroso
Aline F. Pedroso
RKRohan Khera
Rohan Khera

31 October 2026 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
INIbrahim Naoum
Ibrahim Naoum
JPJuliana Perez Pinzon
Juliana Perez Pinzon
MSMiles Shen
Miles Shen
MTMelissa Todice
Melissa Todice
MPMarc Pelletier
Marc Pelletier
AVAmit N. Vora
Amit N. Vora